Clinical trial
Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT…
NCT00134667 · Eyetech Pharmaceuticals, Industry · Terminated
Key facts
| NCT number | NCT00134667 |
|---|---|
| Title | Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photodynamic Therapy) With Visudyne (Verteporfin) in Patients With Age-Related Macular Degeneration (AMD) |
| Official title | A Phase IIIb/IV Randomized, Double-Masked, Active Controlled, Dose-Ranging, Multi-Center Comparative Trial, in Parallel Groups, to Compare the Safety and Efficacy of Intravitreal Injections of Pegaptanib Sodium (Macugen) Given Every 6 Weeks for 102 Weeks, to Pegaptanib Sodium Plus Photodynamic… |
| Lead sponsor | Eyetech Pharmaceuticals, Industry |
| Collaborators | Pfizer Industry |
| Status | Terminated |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Age-Related Macular Degeneration |
| Intervention type | Drug |
| Interventions | Photodynamic Therapy (PDT) with Visudyne (verteporfin), Macugen (pegaptanib sodium) |
| Enrollment | 360 |
| Start date | Mar 1, 2005 |
| Completion | Oct 1, 2008 |
| First posted | Aug 25, 2005 |
| Last update posted | Jan 15, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: